Itau Unibanco Holding S.A. Beam Therapeutics Inc. Transaction History

Itau Unibanco Holding S.A.

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$17.69 - $30.76 $12,683 - $22,054	-717 Reduced 75.24%	236 $6,000
Q3 2023 Nov 14, 2023	BUY	$23.01 - $32.46 $5,062 - $7,141	220 Added 30.01%	953 $22,000
Q2 2023 Aug 14, 2023	BUY	$29.32 - $35.99 $12,900 - $15,835	440 Added 150.17%	733 $23,000
Q1 2023 May 12, 2023	SELL	$30.15 - $48.79 $1,929 - $3,122	-64 Reduced 17.93%	293 $8,000
Q4 2022 Feb 09, 2023	SELL	$36.73 - $51.6 $16,308 - $22,910	-444 Reduced 55.43%	357 $13,000
Q3 2022 Nov 14, 2022	SELL	$39.79 - $70.31 $14,722 - $26,014	-370 Reduced 31.6%	801 $38,000
Q2 2022 Aug 15, 2022	BUY	$29.86 - $62.36 $1,343 - $2,806	45 Added 4.0%	1,171 $45,000
Q1 2022 May 16, 2022	BUY	$53.73 - $82.16 $859 - $1,314	16 Added 1.44%	1,126 $65,000
Q4 2021 Feb 14, 2022	BUY	$68.02 - $99.06 $75,502 - $109,956	1,110 New	1,110 $91,000

236

75.2M

438K

232K

Ticker BEAM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,354,600
Market Cap $1.74B
Description
Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen ...

Get notified when there are updates to the investment portfolio of Itau Unibanco Holding S.A., based on Form 13F filings with the SEC.

Stay updated on Itau Unibanco Holding S.A. with notifications on news.